Daily Cardiology Research Analysis
Analyzed 223 papers and selected 3 impactful papers.
Summary
Analyzed 223 papers and selected 3 impactful articles.
Selected Articles
1. An integrated germline and somatic genomic model for coronary artery disease.
Using UK Biobank and TOPMed, the authors built and validated a unified genomic model integrating polygenic risk, genetically proxied proteomic/metabolomic scores, and clonal hematopoiesis. The model broadened risk gradients and identified about 13% of high-risk individuals missed by polygenic risk scores alone, modestly augmenting clinical Pooled Cohort Equations in middle age.
Impact: Provides a pragmatic, multi-driver genomic framework that outperforms polygenic risk alone and is externally validated, enabling more precise CAD risk stratification from a single DNA sample.
Clinical Implications: May refine primary prevention decisions (e.g., statin initiation, LDL-C targets) by flagging individuals at high CAD risk not captured by polygenic scores, particularly in middle-aged adults when combined with Pooled Cohort Equations.
Key Findings
- An integrated genomic model including PRS, genetically proxied proteomic/metabolomic scores, and CHIP stratified 10-year CAD risk from 1.1% to 15.5% (UKB) and 3.8% to 33.0% (TOPMed).
- The model identified ~13% of high-risk individuals not detected by polygenic risk score alone.
- It modestly augmented the Pooled Cohort Equations’ performance in middle-aged adults.
Methodological Strengths
- Very large discovery and external validation cohorts (UK Biobank and TOPMed).
- Unified modeling of multiple germline and somatic genetic drivers with transparent performance reporting.
Limitations
- Incremental predictive value over PRS at the population level was modest.
- Potential ancestry-specific performance and real-world implementation hurdles were not fully addressed.
Future Directions: Prospective clinical utility studies across ancestries, cost-effectiveness analyses, and integration into EHR workflows to guide preventive therapies.
Multiple germline and somatic genomic factors are associated with risk of coronary artery disease, but there is no single measure of risk that integrates all information from a DNA sample. To address this gap, we develop an integrated genomic model that includes six germline and somatic genetic drivers for coronary artery disease, including polygenic risk score, genetically-proxied proteomic/metabolomic risk scores, and clonal hematopoiesis of indeterminate potential. We evaluated its predictive power in the UK Biobank (N = 391,536), and validate it using data from the TOPMed program (N = 34,177). The 10-year coronary artery disease risk based on the integrated genomic model profile ranges from 1.1% to 15.5% in the UK Biobank and from 3.8% to 33.0% in TOPMed, with a more pronounced gradient in males than females. The integrated genomic model captures the cumulative effect of multiple genetic drivers, identifying individuals at high risk for coronary artery disease despite lacking any single high-risk genetic factor, as well as individuals at low risk despite carrying known high-risk factors. In middle age, the integrated genomic model augments the performance of the Pooled Cohort Equations, a clinical risk calculator for coronary artery disease. While the integrated genomic model yields only modest incremental predictive value over polygenic risk score at the population level, it identifies approximately 13% of high-risk individuals not detected by polygenic risk score alone.
2. Conduction System Pacing Versus Right Ventricular Pacing in Atrioventricular Block: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
Across five randomized trials (n=659), conduction system pacing achieved significantly narrower paced QRS (−28 ms) and a small but significant improvement in LVEF (~+1.3%) compared with right ventricular pacing, without an increase in device/lead-related complications, though procedures were longer. These findings support CSP as a more physiologic pacing strategy for AV block with comparable safety.
Impact: Provides RCT-level synthesized evidence favoring physiologic pacing over conventional RVP, informing device therapy choices and guideline evolution.
Clinical Implications: For patients requiring pacing for AV block, CSP can be preferred to reduce dyssynchrony and preserve LV function, provided operator expertise and system resources are available.
Key Findings
- CSP narrowed paced QRS duration versus RVP (MD −28.44 ms; p<0.01).
- CSP modestly improved LVEF compared with RVP (MD +1.31%; p<0.01).
- Procedure time was longer with CSP (MD +25.86 minutes; p<0.01).
- Device/lead-related complications were comparable between CSP and RVP (RR 1.35; p=0.71).
Methodological Strengths
- Meta-analysis restricted to randomized controlled trials
- Consistent direction of effect across multiple efficacy endpoints
Limitations
- Modest total sample size (n=659) and variability in CSP techniques (HBP vs LBBAP)
- Longer procedure times may reflect learning curve and operator heterogeneity
Future Directions: Larger, longer-term RCTs should evaluate hard clinical outcomes (HF hospitalization, mortality), lead performance/longevity, and cost-effectiveness of CSP versus RVP.
INTRODUCTION: Right ventricular pacing (RVP) is the standard therapy for atrioventricular (AV) block but may cause ventricular dyssynchrony with long-term use. This meta-analysis evaluates the efficacy and safety of conduction system pacing (CSP), including His bundle pacing (HBP) and left bundle branch area pacing (LBBAP), as a physiologic alternative to RVP. METHODS: A systematic search was conducted across PubMed, Google Scholar, Cochrane CENTRAL, and ClinicalTrials.gov from inception to August 2025, for randomized controlled trials (RCTs). Outcomes were analyzed as risk ratios (RRs) or mean differences (MDs) with 95% confidence intervals (CIs) and pooled using the Mantel-Haenszel random-effects model in R (version 4.4.2). RESULTS: Five RCTs en
3. Impact of switching high-sensitivity cardiac troponin assays on risk stratification in suspected acute coronary syndrome.
In a 25,849-patient multicenter cohort, switching from hs-cTnI to hs-cTnT led to far fewer patients meeting low-risk thresholds (17.6% vs 57.3%) and fewer discharges after a single troponin (30% vs 47%). Low-risk patients identified by hs-cTnT were younger with fewer comorbidities and had fewer subsequent cardiovascular events at one year, indicating that assay-specific thresholds are not interchangeable for ED disposition.
Impact: Demonstrates real-world, clinically meaningful differences in ACS triage solely due to assay selection, challenging assumptions of interchangeability.
Clinical Implications: Emergency departments should align pathways and discharge thresholds to the specific hs-cTn assay in use and anticipate downstream impacts on admissions and outcomes.
Key Findings
- Low-risk identification at presentation was much lower with hs-cTnT versus hs-cTnI (17.6% vs 57.3%; p<0.001).
- Discharge after a single troponin measurement was less frequent with hs-cTnT (30% vs 47%; p<0.001).
- Patients classified low-risk by hs-cTnT had fewer subsequent cardiovascular events at 1 year.
- Assay-specific thresholds did not yield equivalent performance for risk stratification.
Methodological Strengths
- Very large, multicenter cohort with a natural experiment (assay switch) design
- Clinically relevant, hard outcomes assessed at one year
Limitations
- Observational, pre–post design vulnerable to temporal and site-level confounding
- Assay thresholds derived from different populations may influence apparent performance
Future Directions: Prospective studies to harmonize or recalibrate assay-specific thresholds and evaluate safety of accelerated discharge pathways by assay.
BACKGROUND: Cardiac troponin is central to risk stratification in patients with suspected acute coronary syndrome. High-sensitivity assays measuring cardiac troponin (hs-cTn) I or T are recommended by international guidelines. However, diagnostic thresholds for these assays are derived from different populations. We aimed to evaluate whether the change in assay influenced risk stratification. METHODS: This is a secondary analysis of the TWITCH-ED study enrolling 25,849 patients with suspected acute coronary syndrome between October 2020 and October 2022. In October 2021, sites changed from a hs-cTnI to a hs-cTnT assay. Study outcomes included discharge from the Emergency Department following a single cardiac troponin measurement, a composite outcome of subsequent myocardial infarction, heart failure hospitalization, or cardiovascular death at one year, and all-cause death at one year. Patients were stratified as low-risk at presentation using established thresholds. RESULTS: Higher proportions of patie